Managing Lung Nodules Using Telemedicine and Molecular Biomarkers During the COVID-19 Pandemic
Chest
.
2020 Oct;158(4):1794-1795.
doi: 10.1016/j.chest.2020.05.574.
Authors
Steven C Springmeyer
1
,
James Jett
2
,
Krish Bhadra
3
,
Fayez Kheir
4
,
Adnan Majid
4
Affiliations
1
Biodesix, Boulder, CO. Electronic address: drstevevalve@gmail.com.
2
Biodesix, Boulder, CO.
3
Rees Skillern Cancer Institute, CHI Memorial Lung Care Associates, Chatanooga, TN.
4
Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
PMID:
33036105
PMCID:
PMC7533686
DOI:
10.1016/j.chest.2020.05.574
No abstract available
Publication types
Letter
Comment
MeSH terms
Betacoronavirus
Biomarkers
COVID-19
Coronavirus Infections*
Early Detection of Cancer
Humans
Lung Neoplasms*
Pandemics*
Pneumonia, Viral*
SARS-CoV-2
Telemedicine*
Substances
Biomarkers